5-Amino-1MQ.

Acting directly on fat tissue to increase fat breakdown or reduce its blood supply.

This pathway groups compounds that act on adipose tissue itself rather than on appetite. Lipolysis is the enzymatic breakdown of stored triglycerides into free fatty acids and glycerol, executed by adipose triglyceride lipase and hormone-sensitive lipase inside the fat cell. It is normally triggered by catecholamines acting on beta-adrenergic receptors, which raise cyclic AMP and activate protein kinase A. Growth hormone also stimulates lipolysis, but it does so as part of a package that includes growth promotion and a rise in insulin resistance. Several compounds here derive from the observation that growth hormone's fat-mobilising activity appears to reside in the carboxy-terminal region of the molecule, separate from the domain that binds and activates the growth hormone receptor. Isolating that region was intended to produce fat breakdown without raising IGF-1 or impairing glucose handling. Mechanistic work in rodents linked the effect to beta-3 adrenergic receptor activity rather than to growth hormone receptor signalling. One member of this group is the plain fragment; another is a modified analog with an added amino-terminal residue and considerably more development history behind it. A second, entirely different approach targets the blood supply instead of the fat cell. A homing sequence binds prohibitin, a protein unusually abundant on the endothelial cells lining blood vessels within white adipose tissue, and delivers a pro-apoptotic sequence that kills those cells once internalised. The intent is to shrink fat depots by starving them of perfusion. This is a vascular-targeting strategy borrowed from oncology and is conceptually unrelated to lipolysis. A third approach targets an enzyme, nicotinamide N-methyltransferase, which is highly expressed in adipose tissue and consumes both nicotinamide and methyl groups from S-adenosylmethionine. Inhibiting it is proposed to spare nicotinamide for NAD+ regeneration and to shift adipocytes toward energy expenditure rather than storage. Clinical relevance across this group is weak. The growth hormone fragment analog was carried into human obesity trials and did not produce clinically meaningful weight loss beyond placebo, and it was not approved as a medicine. The plain fragment has essentially no human evidence of its own and borrows its reputation from that analog. The vascular-targeting compound raised kidney toxicity concerns in primate work and did not progress. The enzyme inhibitor's downstream logic is plausible but largely inferred from animal and cell studies. None of these are approved for any use.

Targeting senescent cells, telomere maintenance, and NAD+ availability.

Cellular senescence is a state in which a damaged cell permanently stops dividing but does not die. Senescent cells accumulate with age and secrete a mix of inflammatory cytokines, proteases, and growth factors collectively called the senescence-associated secretory phenotype, which is thought to drive chronic low-grade inflammation in surrounding tissue. Clearing these cells in animal models has been associated with improvements in several age-related measures, which is the entire premise behind senolytic compounds. One compound here exploits a specific vulnerability. In senescent cells the transcription factor FOXO4 accumulates and binds the tumour suppressor p53, holding it in the nucleus and preventing it from triggering apoptosis. That interaction is what keeps a damaged cell alive when it should have died. A retro-inverso peptide designed to disrupt the FOXO4 and p53 interface frees p53 to initiate intrinsic apoptotic signalling. Because healthy cells do not depend on this interaction for survival, the effect is proposed to be selective for senescent cells. A second approach targets telomere maintenance. Telomeres shorten with each cell division until a cell reaches its replicative limit, and telomerase is the enzyme that can extend them. A short peptide in this group has been reported in cultured human cells to induce telomerase expression and extend the number of divisions past that limit, with a secondary proposed action on pineal function and melatonin output. A third targets NAD+ availability by inhibiting the enzyme that methylates nicotinamide and diverts it away from NAD+ salvage. NAD+ is a substrate for sirtuins and a central currency of cellular energy metabolism, and its decline with age is a well-described observation. Honesty about this pathway is essential. Senescence biology is real and actively researched, and the molecular interactions described above have been characterised in cells and rodents. What is missing is human evidence. There are no controlled clinical trials demonstrating that any of these compounds slow ageing, extend healthy lifespan, or improve any clinical outcome in people. Deliberately inducing apoptosis or manipulating telomerase activity also carries theoretical risks that have not been characterised in humans, since telomerase reactivation is a feature of many cancers. None of these compounds is approved anywhere, and all are sold as unregulated research material.

Weight and adipose findings come from diet-induced obese mice; no human data has been published.

It is a small-molecule methylquinolinium NNMT inhibitor, despite being sold alongside research peptides.

The appetite-independent weight change was observed in rodents, not in people.

It is not a recognized dietary supplement, and human toxicology, interaction and long-term data do not exist.